On the heels of an NDA submission for brepocitinib in dermatomyositis, Priovant Therapeutics Inc. disclosed data showing the dual TYK2/JAK1 inhibitor surpassed expectations in a phase II study in cutaneous sarcoidosis, another chronic inflammatory skin condition with limited treatment options, setting the stage for a phase III study set to start this year.
Trumprx.gov launched with much fanfare late Feb. 5, and the online tool brings promise for the “world’s lowest prices” on prescription drugs. Alongside the website hoopla came word from Hims & Hers Health of its own steep discounts on what’s to be the compounded version of a Trumprx-featured therapy: oral Wegovy (semaglutide) for obesity. Novo Nordisk A/S, Wegovy’s originator, vowed to fight.
Scientists at Ghent University have created a mouse model that incorporates human versions of the receptors that recognize the fragment crystallizable region of immunoglobulin G, one of the most abundant antibodies in the blood and a key mediator of essential immune functions such as cellular activation, pathogen elimination and the regulation of inflammatory responses.
Regulatory snapshots for biopharma and med tech, including global submissions and approvals, and other regulatory decisions and designations: Acarix, Balt, Cumberland, Hologic, Ingeneron, Oncolytics, TSC.
Biopharma and med-tech happenings, including deals and partnerships, and other news in brief: Ayrmid, Biodexa, Biomica, DT Cloud Star, Entera, Evogene, Invacare, Lishan, Opko, Otsuka, Primegen, T2 Biosystems, Zevra.
Clinical updates for biopharma and med tech, including data readouts and publications: Adagio Medical, Biogen, Immunic, Pharmazz, Spur, Theralase, Tr1x.
Biopharma and med-tech companies raising money in public or private financings, including: Biolab, Exxel, Imbed, Izotropic, Pavmed, Stratus, Third Arc.
New hires and promotions in the biopharma and med-tech industries, including: Aprea, Levicept, Lumicell, Mercy Bioanalytics, Nodthera, Providence Medical Technology, Rivus, United Imaging, Zoll.